NKS-01

Drugs of the Future

Volumn 21, Issue 10, 1996, Pages 1028-1031

  Graul, A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

14ALPHA HYDROXYANDROST 4 ENE 3,16,17 TRIONE; AMINOGLUTETHIMIDE; ANTINEOPLASTIC AGENT; AROMATASE; AROMATASE INHIBITOR; ESTROGEN RECEPTOR; FADROZOLE; NKS 01; TAMOXIFEN; TESTOSTERONE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; DRUG SYNTHESIS; ENZYME INHIBITION; FEMALE; HUMAN; IN VITRO STUDY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; SHORT SURVEY; TUMOR CELL; UTERUS;

EID: 0029854118     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1996.021.10.376472     Document Type: Short Survey

References (26)

1. Nakakoshi, M., Tamura, K., Yoshihama, M., Miyata, N. (Snow Brand Milk Prods. Co., Ltd.). Process for preparing 14α-hydroxy-4-androstene-3,6,17-trione. EP 382162.
2. Yoshihama, M., Tamura, K., Miyata, N., Nakayama, S., Nakakoshi, M. (Snow Brand Milk Prods. Co., Ltd.). Novel and rost-4-ene-3, 17-dione derivs, and process for their preparation. JP 88192794, JP 88192795, JP 88192796, JP 88192797, US 4975368, WO 8805781.
3. Yoshihama, M., Nakakoshi, M., Tamura, K., Miyata, N., Kawanishi, G., Iida, M. Microbial production of two new dihydroxylated androstenedione derivatives by Acremonium strictum. J Ferment Bioeng 1989, 67(4): 238-43.
4. Nakakoshi, M., Yoshihama, M., Nakamura, H. et al. (Snow Brand Milk Prods. Co., Ltd.). New manufacturing method for 14α-hydroxy-4-androsten-3,6, 17-trione. JP 9307687.
5. Seya, M., Nakamura, H., Nakakoshi, M. (Snow Brand Milk Prods. Co., Ltd.). Process for the preparation of 14α-hydroxy-4-androsten-3,6, 17-thone. JP 91068596.
6. Yoshioka, H., Asada, H., Fujita, S. (Nippon Kayaku Co., Ltd.). Process for production of 6β, 14α-dihydroxy-4-androstene-3, 17-dione. EP 599658.
7. Wakeling, A.E., Bowler, J. Biology and mode of action of pure antioestrogens. J Steroid Biochem 1988, 30: 141-7.
8. Wakeling, A.E., Bowler, J. Novel antioestrogens without partial agonist activity. J Steroid Biochem 1988, 31: 645-53.
9. Conn, P.M., Crowley, W.F. Gonadotropin-releasing hormone and its analogs. N Engl J Med 1991, 324: 93-103.
10. Thompson, E.A., Siiteri, P.K. The involvement of human placental microsomal cytochrome P-450 in aromatization. J Biol Chem 1974, 249: 5373-8.
11. Thompson, E.A., Siiteri, P.K. Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. J Biol Chem 1974, 249: 5364-72.
12. Schwarzel, W.C., Kruggel, W.G., Brodie, H.J. Studies on the mechanism of estrogen biosynthesis. VIII. The development of inhibitors of the enzyme system in human placenta. Endocrinology 1973, 92: 866-80.
13. Tan, L., Hrycay, E.G., Matsumoto, K. Synthesis and properties of the epimeric 6-hydroperoxyandrostenediones, new substrate/ inhibitors of human placental aromatase. J Steroid Biochem 1983, 19: 1329-38.
14. Marsh, D.A., Brodie, H.J., Garret, W., Tsai-Morris, C., Brodie, A.M.H. Aromatase inhibitors. Synthesis and biological activity of androstenedione derivatives. J Med Chem 1985, 28: 788-95.
15. Royce, C. Formestane. Drugs Fut 1993, 18(7): 599.
16. Tan, L., Rousseau, P. The aromatase active site: The C-6 "front" side of the androgen molecule is required for binding. Biochem Biophys Res Commun 1987, 147: 1259-67.
17. Yoshihama, M., Tamura, K., Nakakoshi, M., Nakamura, J., Fujise, N., Kawanishi, G. 14α-Hydroxyandrost-4-ene-3,6, 17-trione as a mechanical-based irreversible inhibitor of estrogen biosynthesis. Chem Pharm Bull 1990, 38(10): 2834-7.
18. Yamamoto, T., Fukuoka, M., Fujimoto, Y., Kitawaki, J., Nakakoshi, M., Yohsihama, M., Okada, H. Inhibitory effect of a new androstenedione derivative, 14α-hydroxy-4-androstene-3,6, 17-trione (14α-OHAT) on aromatase activity of human uterine tumors. J Steroid Biochem 1990, 36(6): 517-21.
19. Kitawaki, J., Fukuoka, M., Yamamoto, T., Honjo, H., Okada, H. Contribution of aromatase to the deoxyribonucleic acid synthesis of MCF-7 human breast cancer cells and its suppression by aromatase inhibitors. J Steroid Biochem Mol Biol 1992, 42(3/4): 267-77.
20. Kitawaki, H., Kim, T., Kanno, H., Noguchi, T., Yamamoto, T., Okada, H. Growth suppression of MCF-7 human breast cancer cells by aromatase inhibitors: A new system for aromatase inhibitor screening. J Steroid Biochem Mol Biol 1993, 44(4-6): 667-70.
21. Fukuoka, M. Antitumor effects of aromatase inhibitors on the growth of estrogen dependent tumors. J Kyoto Prefect Univ Med 1992, 101(3): 317-33.
22. Kubota, T., Suto, A., Kitajima, M., Nakamura, J., Yoshihara, M., Sasano, H., Hoffman, R.M. Effects of a new aromatase-inhibitor discovery screen using breast cancer specimens in the histoculture drug response assay. Breast Cancer Res Treat 1996, 37(Suppl): Abst 226.
23. Yoshihama, M., Nakamura, J., Fujise, N., Yamashita, Y. Potency and specificity of NKS01 as an aromatase inhibitor and its pharmacological profiles. Proc Amer Assoc Cancer Res 1993, 34: Abst 1400.
24. Fujise, N., Yamashita, Y., Takaoka, H., Honda, N., Yoshihama, M. (Snow Brand Milk Prods. Co., Ltd.). Use of steroid derivatives in the treatment of endomethosis. EP 451869, JP 91294230, US 5166200.
25. Sumida, H., Moriya, T., Handa, J., Yamashita, T., Nakamori, K., Nishizuka, M., Arai, Y. A procedure for estimating developmental toxicity using sexually dimorphic regions of the rat brain. Teratology 1995, 52(4): Abst P-26.
26. Sumida, H., Moriya, T., Handa, J., Yamashita, T., Nakamori, K., Nishizuka, M., Arai, Y. A procedure for estimating developmental toxicity using sexually dimorphic regions of the rat brain. Congenital Anomalies 1995, 35(3): Abst P-26.